AGM Statement

RNS Number:8500N
BTG PLC
23 July 2003

23 July 2003

                          BTG plc: 2003 AGM Statement
                  Licence agreement with Abiogen Pharma S.p.A
      Collaboration with Taiwan's Industrial Technology Research Institute


BTG plc (LSE: BGC), the global technology commercialisation company, will hold
its Annual General Meeting today at 10.30am at the company's London offices.
The following is a summary of comments to be made by Dr Jack Leonard, Chairman,
and Ian Harvey, Chief Executive Officer.

"BTG's results for the year ended 31 March 2003 were broadly in line with the
Board's expectations and reflected both the external environment and the
company's restructuring in December 2002.  As previously indicated, we expect
this year's results to show the benefits of the restructuring.  We started the
new financial year with cash reserves of #61.1 million, and are continuing to
invest selectively in the acquisition, development and commercialisation of
technologies in our focus areas.

"We have increased the efficiency of our technology screening processes, with
six technology acquisitions already completed this financial year and options
held over three others.  These technologies are from both existing and new
sources, the latter including Cornell Research Foundation and Brown University
in the US, and N.V. Organon, part of Akzo Nobel Pharma, in Europe.

"In development, we are pleased to have signed an agreement with Taiwan's
Industrial Technology Research Institute, in which we will jointly develop and
BTG will commercialise a patented polymer technology for flexible organic/
polymer light-emitting diode (OLED/PLED) information displays.  These displays
reduce power consumption and improve both brightness and contrast and as such
are expected to replace liquid crystal displays in the next generation of laptop
computers, PDAs, mobile telephones and television sets.

"Our wholly-owned subsidiary company Provensis has continued to develop
VARISOLVE(R) Microfoam.  Work has begun to establish a facility in North Wales
for final assembly and manufacture of the product. In the US, the phase II trial
continues.  The final study report from the recently completed European Phase
III trial is expected in the autumn.  Preliminary results from this trial will
be presented at the International Union of Phlebology (UIP) World Congress in
San Diego, USA, on 30 August and will be announced by BTG at that time.

"In commercialisation, we have had an encouraging first quarter and are on track
to deliver the anticipated resumption in revenue growth this year, as
technologies that have been progressing through development are successfully
commercialised.  Today we have announced that we have licensed two compounds to
Abiogen Pharma S.p.A, for which we will receive #2 million in upfront payments,
significant development milestone payments and royalties on net sales.  These
compounds are the first in a new class of non-sedating, non-addictive drugs that
may offer significant advantages over other treatments for anxiety and
depression.

"CAMPATH(R) (alemtuzumab), a treatment for chronic lymphocytic leukaemia, is
continuing to gain acceptance by physicians.  On 21 July, our licensee ILEX
Oncology, Inc. reported a fourth consecutive quarter of sales growth.  Sales of
CAMPATH(R) by ILEX's partners Schering AG of Germany and its US affiliate Berlex
Laboratories, Inc. reached $23.3 million during the second quarter of 2003,
approximately 20% higher than the first quarter, as a result of which ILEX now
anticipates full year 2003 sales will exceed $60 million compared with its
original estimate of sales in excess of $50 million.

"We look forward to reporting further progress across the portfolio during the
year."

                                      Ends



For further information contact:


BTG                                                     Financial Dynamics
Andy Burrows, Director of Investor Relations            Ben Atwell
[phone]                                     [phone]


About BTG

BTG finds, develops and commercializes emerging technologies in the life and
physical sciences. These innovations are protected by a strong portfolio of
intellectual property that BTG develops and enhances. BTG then captures the
value in these technologies through licensing and venturing activities. From the
origins of its business in 1949, BTG has commercialized major innovations such
as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting
protein, CAMPATH(R) (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is
quoted on the London Stock Exchange under the symbol "BGC" and operates from
offices in London and Philadelphia, with representation in Tokyo. BTG operates
through wholly owned subsidiaries, BTG International Ltd. and BTG International
Inc. in the UK and USA, respectively. Further information on BTG can be found at
www.btgplc.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMRTMPTMMBTBJJ